WO2022026807A3 - Antibodies targeting sars-cov-2 and uses thereof - Google Patents

Antibodies targeting sars-cov-2 and uses thereof Download PDF

Info

Publication number
WO2022026807A3
WO2022026807A3 PCT/US2021/043866 US2021043866W WO2022026807A3 WO 2022026807 A3 WO2022026807 A3 WO 2022026807A3 US 2021043866 W US2021043866 W US 2021043866W WO 2022026807 A3 WO2022026807 A3 WO 2022026807A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
cov
fragments
antibodies targeting
antigen
Prior art date
Application number
PCT/US2021/043866
Other languages
French (fr)
Other versions
WO2022026807A2 (en
Inventor
Ryan MALONIS
George Georgiev
Karen TONG
Jonathan R. Lai
Kartik Chandran
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of WO2022026807A2 publication Critical patent/WO2022026807A2/en
Publication of WO2022026807A3 publication Critical patent/WO2022026807A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to an antigen from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), compositions comprising such antibodies and/or fragments, as well as methods of use and devices employing such antibodies and/or fragments. Further disclosed are heavy chain and light chain variable region sequences and complementarity determining regions (CDR) sequences of the antibodies.
PCT/US2021/043866 2020-07-30 2021-07-30 Antibodies targeting sars-cov-2 and uses thereof WO2022026807A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063058621P 2020-07-30 2020-07-30
US63/058,621 2020-07-30

Publications (2)

Publication Number Publication Date
WO2022026807A2 WO2022026807A2 (en) 2022-02-03
WO2022026807A3 true WO2022026807A3 (en) 2022-03-24

Family

ID=80036091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/043866 WO2022026807A2 (en) 2020-07-30 2021-07-30 Antibodies targeting sars-cov-2 and uses thereof

Country Status (1)

Country Link
WO (1) WO2022026807A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056111A1 (en) * 2020-08-11 2022-02-24 Yurogen Biosystems Llc MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288276A1 (en) * 2001-10-19 2014-09-25 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
US20150337029A1 (en) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
US20180022825A1 (en) * 2016-05-25 2018-01-25 Novartis Ag REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF
US20180326084A1 (en) * 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288276A1 (en) * 2001-10-19 2014-09-25 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
US20150337029A1 (en) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
US20180326084A1 (en) * 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
US20180022825A1 (en) * 2016-05-25 2018-01-25 Novartis Ag REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALCIOGLU ET AL.: "SARS-CoV-2 neutralizing antibody development strategies", TURK J BIO L, vol. 44, no. 3, 2020, pages 203 - 214, XP055821470, DOI: 10.3906/biy-2005-91 *
CHEN ET AL.: "Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor", CELL MOL IMMUNOL, vol. 17, no. 6, June 2020 (2020-06-01), pages 647 - 649, XP037433894, DOI: 10.1038/s41423-020-0426-7 *
DATABASE UniprotKB LAVSTSEN T. , JESPERSEN J.S.: "Tetraspanin", XP055919361, retrieved from Uniprot Database accession no. A0A1A8PY90 *
DATABASE UniprotKB SCHEEPERS C. , MORRIS L.: "IGL c46_light_IGKV3-11_IGKJ4", XP055919387, retrieved from Uniprot Database accession no. A0A5C2FV57 *
LV ZHE, DENG YONG-QIANG, YE QING, CAO LEI, SUN CHUN-YUN, FAN CHANGFA, HUANG WEIJIN, SUN SHIHUI, SUN YAO, ZHU LING, CHEN QI, WANG N: "Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 369, no. 6510, 18 September 2020 (2020-09-18), US , pages 1505 - 1509, XP055811875, ISSN: 0036-8075, DOI: 10.1126/science.abc5881 *
TOWNSEND CATHERINE L., LAFFY JULIE M. J., WU YU-CHANG BRYAN, SILVA O’HARE JOSELLI, MARTIN VICTORIA, KIPLING DAVID, FRATERNALI FRAN: "Significant Differences in Physicochemical Properties of Human Immunoglobulin Kappa and Lambda CDR3 Regions", FRONTIERS IN IMMUNOLOGY, vol. 7, XP055919190, DOI: 10.3389/fimmu.2016.00388 *
WAN ET AL.: "Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection", CELL REP, vol. 32, 21 July 2020 (2020-07-21), XP055773465, DOI: 10.1016/j.celrep.2020.107918 *

Also Published As

Publication number Publication date
WO2022026807A2 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
IL299221A (en) Cd3 binding antibodies
WO2007058823A3 (en) Anti-egfr antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
RU2531523C3 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
MX2019007848A (en) Anti-pd-1 antibodies and uses thereof.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2019118984A (en) ANTIBODIES AIMED AGAINST INTERLEUKIN-33 (IL-33)
MX2020003087A (en) Novel anti-cd3epsilon antibodies.
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
RS52332B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
IL250289B2 (en) Angiopoietin-like 4 antibodies and methods of use
RU2018106456A (en) ANTIBODY TO EPHA4
WO2019147863A3 (en) Mica/b antibodies and methods of use
AR110967A1 (en) MIMETIC ANTIBODIES FGF21 AND ITS USE
WO2020257789A3 (en) Anti-tim-3 antibodies
WO2022026807A3 (en) Antibodies targeting sars-cov-2 and uses thereof
MX2021015156A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof.
AU2012293646A8 (en) New antibodies against phosphorylcholine
WO2020028428A3 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21850009

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21850009

Country of ref document: EP

Kind code of ref document: A2